Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genelux Corp. ( (GNLX) ) has shared an update.
On January 8, 2026, Genelux Corporation entered into an underwriting agreement with Lucid Capital Markets to conduct an underwritten public offering of 6,666,667 shares of its common stock at $3.00 per share, all sold by the company, for expected gross proceeds of about $20 million before fees, with closing anticipated on January 9, 2026 subject to customary conditions. The equity raise, launched via press announcements on January 7 and January 8, 2026 under an effective shelf registration, reinforces Genelux’s access to capital markets and is expected to provide additional funding flexibility as it advances its late-stage immuno-oncology pipeline, with terms that include standard representations, indemnification provisions and an option for the underwriter to purchase additional shares.
The most recent analyst rating on (GNLX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.
Spark’s Take on GNLX Stock
According to Spark, TipRanks’ AI Analyst, GNLX is a Neutral.
The score is held down primarily by very weak operating fundamentals (minimal revenue, large losses, and heavy cash burn) and bearish technicals. Positive corporate developments (encouraging interim trial readouts and a leadership upgrade) provide some offset, but valuation offers little support while the company remains loss-making.
To see Spark’s full report on GNLX stock, click here.
More about Genelux Corp.
Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients with aggressive and hard-to-treat solid tumors. Its lead candidate, Olvi-Vec, is being evaluated in multiple U.S. and China-based clinical trials across ovarian cancer, non-small-cell lung cancer and small-cell lung cancer, leveraging the company’s proprietary CHOICE platform of engineered oncolytic vaccinia virus product candidates.
Average Trading Volume: 237,259
Technical Sentiment Signal: Sell
Current Market Cap: $129M
For detailed information about GNLX stock, go to TipRanks’ Stock Analysis page.